Uncategorized
Phase 3 trial of Roclatan begins in Europe
Aerie Pharmaceuticals has begun patient dosing in a phase 3 European trial of Roclatan for lowering IOP in patients with open-angle glaucoma or ocular hypertension, according to a company press release.Roclatan (netarsudil 0.02%/latanoprost 0.005% ophthalmic solution) is a once-daily eye drop. The two-arm, 6-month Mercury 3 safety trial will enroll approximately 500 patients and provide a 90-day interim efficacy readout comparing the fixed-dose combination therapy to Ganfort (bimatoprost/timolol, Allergan), the release said.